ELCC 2016 | Biomarkers and lung cancer: Current status

Keith Kerr • 15 Apr 2016

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Keith Kerr, BSc, MB ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, United Kingdom, discusses biomarker-based selection of therapy and the progress in understanding clinically relevant biomarkers in patients with lung cancer.

Pathology training in the molecular era

Keith Kerr • 24 Jan 2019

Challenges of biomarker testing in the UK

Keith Kerr • 26 Apr 2023

Problems with PD-L1 expression testing in patients with NSCLC

Keith Kerr • 11 Apr 2018

Biostatistics: can we produce more valid results from trials?

Keith Kerr • 25 Jan 2018

Related Videos

Treatment implications from highly selective patient selection in clinical trials

Frank Griesinger • 18 Jan 2019

The JAVELIN 100 study: a trial to improve lung cancer treatment

Martin Reck • 21 Sep 2017

Role of early lung cancer screening in cigarette smokers

Lion Shahab • 26 Nov 2018

Lung cancer screening in the UK: CRUK, UK NSC, Public Health England & NHS England

Sara Hiom • 6 Feb 2019